Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan · Delayed Price · Currency is TWD 73.50
+0.10 (0.14%)
Sep 8, 2026, 1:48 PM CST
TPEX:7427 Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 76.27 | 29.84 | 155.06 | 179.55 | 111.08 | 62.79 |
Short-Term Investments | 622.7 | 417.7 | 427.7 | 297 | 136.5 | 62.32 |
Cash & Short-Term Investments | 698.97 | 447.54 | 582.76 | 476.55 | 247.58 | 125.1 |
Cash Growth | 39.63% | -23.20% | 22.29% | 92.48% | 97.90% | 86.65% |
Accounts Receivable | 3.38 | 0.06 | 0.72 | 0.09 | - | - |
Other Receivables | 5.09 | 0.75 | 0.67 | 0.47 | 0.1 | 0.07 |
Receivables | 8.47 | 0.81 | 1.39 | 0.56 | 0.1 | 0.07 |
Inventory | 9.31 | 7.3 | 3.01 | 6.16 | - | - |
Prepaid Expenses | 0.59 | 0.26 | 0.61 | 0.38 | 0.76 | 0.01 |
Other Current Assets | 7.08 | 10.55 | 10.93 | 1.8 | 3.01 | 0.22 |
Total Current Assets | 724.41 | 466.45 | 598.7 | 485.45 | 251.45 | 125.41 |
Property, Plant & Equipment | 7.85 | 9.88 | 13.63 | 16.01 | 0.12 | 0.12 |
Other Intangible Assets | 25.9 | 27.1 | 27.53 | 29.16 | 15.27 | 88.6 |
Long-Term Deferred Charges | 3.73 | 3.09 | 2.78 | 6.96 | 5.94 | 3.5 |
Other Long-Term Assets | 21.84 | 20.24 | 19.95 | 23.67 | 15.92 | 12.34 |
Total Assets | 783.73 | 526.75 | 662.6 | 561.25 | 288.71 | 229.96 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.57 | 0.4 | 0.11 | 0.62 | 0.83 | 0.86 |
Accrued Expenses | 16.31 | 13.88 | 17.6 | 10.05 | 10.63 | 20.42 |
Current Portion of Leases | 3.1 | 3.02 | 2.9 | 2.87 | - | - |
Other Current Liabilities | 2.24 | 2.04 | 1.22 | 2.39 | 0.59 | 0.33 |
Total Current Liabilities | 27.22 | 19.34 | 21.82 | 15.93 | 12.05 | 21.61 |
Long-Term Leases | 2.88 | 4.43 | 7.45 | 10.88 | - | - |
Total Liabilities | 30.1 | 23.77 | 29.28 | 26.81 | 12.05 | 21.61 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 540.26 | 437.06 | 436.44 | 383.58 | 292.87 | 225.75 |
Additional Paid-In Capital | 959.97 | 753.54 | 742.07 | 591.12 | 363.05 | 221.94 |
Retained Earnings | -701.63 | -642.65 | -545.18 | -440.26 | -379.26 | -239.34 |
Treasury Stock | -44.97 | -44.97 | - | - | - | - |
Shareholders' Equity | 753.63 | 502.98 | 633.32 | 534.44 | 276.66 | 208.36 |
Total Liabilities & Equity | 783.73 | 526.75 | 662.6 | 561.25 | 288.71 | 229.96 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 5.98 | 7.45 | 10.36 | 13.75 | - | - |
Net Cash (Debt) | 692.99 | 440.09 | 572.4 | 462.8 | 247.58 | 125.1 |
Net Cash Growth | 40.95% | -23.12% | 23.68% | 86.93% | 97.90% | 86.65% |
Net Cash Per Share | 15.63 | 10.22 | 13.89 | 12.76 | 10.25 | 5.93 |
Filing Date Shares Outstanding | 52.92 | 42.6 | 43.64 | 38.36 | 29.29 | 22.57 |
Total Common Shares Outstanding | 52.92 | 42.6 | 43.64 | 38.36 | 29.29 | 22.57 |
Working Capital | 697.2 | 447.11 | 576.87 | 469.52 | 239.41 | 103.8 |
Book Value Per Share | 14.24 | 11.81 | 14.51 | 13.93 | 9.45 | 9.23 |
Tangible Book Value | 727.74 | 475.89 | 605.79 | 505.28 | 261.39 | 119.75 |
Tangible Book Value Per Share | 13.75 | 11.17 | 13.88 | 13.17 | 8.93 | 5.30 |
Machinery | 7.91 | 7.91 | 7.63 | 5.69 | 3.2 | 3.21 |